Polytrim®
Polymyxin B / Trimethoprim · ophthalmic solution
Antibiotic
Approved uses
Acute bacterial conjunctivitis
1 drop in the affected eye(s) every 3 hours, maximum 6 doses per day, for 7 to 10 days in mild to moderate infection
Clinical cure in 96% of children by day 7 to 10, matching moxifloxacin.
Bacterial blepharoconjunctivitis
1 drop in the affected eye(s) every 3 hours, maximum 6 doses per day, for 7 to 10 days in mild to moderate infection
Contraindications
Known hypersensitivity to any component of the product.
Ophthalmic solution, 10 mL opaque white LDPE dispenser bottle, polymyxin B sulfate 10,000 units/mL, trimethoprim sulfate equivalent to 1 mg/mL, benzalkonium chloride 0.04 mg/mL preservative
Trimethoprim binds and reversibly inhibits bacterial dihydrofolate reductase, blocking production of tetrahydrofolic acid from dihydrofolic acid, and because that binding is stronger for the bacterial than the mammalian enzyme it selectively interferes with bacterial nucleic acid and protein synthesis across gram-positive and gram-negative ophthalmic pathogens. Polymyxin B, a cyclic lipopeptide, is bactericidal for a variety of gram-negative organisms, especially Pseudomonas aeruginosa, and increases bacterial cell membrane permeability by interacting with the membrane phospholipids.
Warnings & Precautions
- Not for injection into the eye: The label states that the solution is not for injection into the eye.
- Hypersensitivity reaction: Discontinue use if one occurs; if hypersensitivity reactions such as redness, irritation, swelling, or pain persist or increase, discontinue use immediately and contact a physician.
- Ophthalmia neonatorum: Not indicated for prophylaxis or treatment.
- Superinfection: Prolonged use may allow overgrowth of nonsusceptible organisms, including fungi; if superinfection occurs, initiate appropriate therapy.
- Contact lens wear: Lenses should not be worn while signs and symptoms of ocular bacterial infection are present.
- Contamination: Avoid contaminating the applicator tip with material from the eye, fingers, or other source, so that the drops stay sterile.
Common Side Effects
The most frequent adverse reaction is local irritation consisting of increased redness, burning, stinging, and/or itching, which may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and anaphylaxis have been reported. Photosensitivity has been reported in patients taking oral trimethoprim.
Pregnancy: Trimethoprim was teratogenic in rats at oral doses 40 times the human dose and, in some rabbit studies, increased fetal loss at oral doses 6 times the human therapeutic dose; no animal reproduction studies exist for polymyxin B, and because folic acid metabolism may be affected, use only if the potential benefit justifies the potential fetal risk.
Lactation: Excretion in human milk is unknown, so caution is warranted in a nursing woman.
Safety and effectiveness below 2 months of age have not been established.